The following sources give you the unfiltered picture - clinical evidence, regulatory context, and safety data straight from the organizations that publish it: FDA.gov - official FDA communications on compounded semaglutide, tirzepatide, and the 503B Bulks List proposal (April 30, 2026)
Individual results vary based on starting weight, dosage, adherence to lifestyle modifications, and metabolic factors
Tirzepatide (Mounjaro) is only available as an injectable formulation for type 2 diabetes management
The same active ingredient is also sold as Ozempic for type 2 diabetes, though Ozempic carries lower maximum doses
Ozempic: key differences Both medications can be highly effective, but their form, frequency, and personal convenience factors might make one a better fit than the other